Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes

NCT00948168 · Completed

Last updated 2026-05-28

This clinical trial tested the effect of exenatide, a medication, on blood sugar control in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 34 people

Who can join Ages 40–80 · all sexes

Timeline Started 2008-07 · est. completion 2009-07

Where 1 site · Belgium

What this study is testing ClinicalTrials.gov NCT00948168 ↗

Description as written by the study sponsor.

The purpose of this study is to determine in type 2 diabetic patients in secondary failure to combined oral therapy whether, besides improvement in glycemic control, addition of exenatide, a new drug introduced to treat diabetes before addition of insulin to current therapy, over 6 months is associated with improvement in beta-cell function, insulin sensitivity following 24-hours discontinuation of the drug.

Treatments tested

exenatide (Byetta) Drug

all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months

Main thing measured	Improvement in HbA1c
Sponsor	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00948168 ↗